




ANNUAL REPORT

2016/2017



Medical Technology
ASSOCIATION OF AUSTRALIA

www.mtaa.org.au



MedTech for a Healthy Australia



Global advances
in MedTech over
past 20 yrs have
resulted in:

- 16% decline in annual mortality
- 25% decline in disability rates
- 56% reduction in hospital days
- 3.2 yr increase in life expectancy

Improving patient lives THROUGH THE ADVANCEMENT OF MEDICAL SCIENCE



Diagnosis, prevention,
treatment + management
of disease & disability

CONTENTS

| | |
|----------------------------|----|
| About MTAA | 3 |
| Chair Report | 4 |
| CEO Report | 7 |
| Board of Directors | 10 |
| Committees | 13 |
| Special Interest Groups | 16 |
| MTAA Representing Industry | 17 |
| Professional Development | 18 |
| Annual Conference 2016 | 19 |
| 2016 Industry Awards | 21 |
| Events | 23 |
| Our Members | 25 |

ABOUT MTAA

The Medical Technology Association of Australia (MTAA) is the national association for the medical technology industry. MTAA ensures the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community.

MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. MTAA members supply the majority of the non-pharmaceutical products used in the treatment of disease and disability in Australia. The range of medical technology is diverse, from familiar items such as syringes and wound dressings through to sophisticated devices such as pacemakers, defibrillators, hip and other prosthetic implants. Products range from 3-D additive manufacturing to robotic surgery equipment and complex hospital installations, in vitro diagnostics, radiation therapy machinery, diagnostic imaging equipment such as ultrasounds and magnetic resonance imaging machines, and eHealth and remote monitoring devices.

Our members also play a vital role in providing healthcare professionals with essential education and training. Industry sponsored fellowships and funding for research and development in hospitals, universities and research facilities helps ensure safe and effective use, development and commercialisation of medical technology.

Associate members are supporter or partner organisations and individuals who work with MedTech companies along the MedTech value chain all the way from idea to patient. They include legal, logistic, consulting practitioners, compliance agencies, health economists, researchers and universities, as well as industrial designers and product commercialisation specialists. They bring valuable expertise and input to the industry.

Our Corporate Goals

1. To be recognised as the national body that represents the medical technology sector with a united voice
2. To ensure the medical technology sector is sustainable
3. To be an influential partner in the healthcare and industry policy debate
4. To provide leadership in ethical interactions with the Australian healthcare community
5. To deliver indispensable value to members

Our People

Ian Burgess, Chief Executive Officer

Allison Fox, Director of Business Operations

Andrea Kunca, Director of Policy and Access

Val Theisz, Director of Regulatory Affairs

Polo Guilbert-Wright, Government Relations and Communications Manager

Lee Grow, Professional Development Manager

Jennifer Ellis, Events & Engagement Manager

Joanne Ince, Events Coordinator (maternity leave)

Kiran Sandhu, Code of Practice Coordinator

Kristina Ek, Executive Assistant & Office Manager

Michael Osborne, Marketing Coordinator

Edwin Ho, Policy Officer

Sandy Gokani, Accounts Officer (part-time)



Medical Technology
ASSOCIATION OF AUSTRALIA

CHAIR REPORT

GAVIN FOX-SMITH

The 2016-17 financial year has been one of challenge and change for the Medical Technology Industry in Australia. I want to thank all of you for your contribution and support as our industry confronted a very disruptive period.

I have had the privilege of working in the medical device industry for three decades, including the last three years as Chair of the Medical Technology Association of Australia (MTAA). While change has been a constant in our industry, what hasn't changed is the dedication and commitment of the more than 19,000 professionals working to make a positive difference to patients' lives through innovative medical technology. I am proud to work alongside you and proud to have led the MTAA during this critical juncture for our industry.

The Australian healthcare system is world class and so is our MedTech industry, bringing research and innovation, improved health outcomes, manufacturing, employment, education and training which positively impacts the Australian community and the economy. Advances in healthcare and patient outcomes are simply not possible without our industry and our work reduces costs and recovery times in the healthcare space.

Global advances in medical technology over the past 20 years have resulted in a 56 per cent reduction in hospital stays, a 25 per cent decline in disability rates, a 16 per cent decline in annual mortality and increased life expectancy of more than three years. That is a record to be proud of.



Agreement with the Federal Government

Earlier this year, the Government announced \$86 million in savings from the Prostheses List which came into effect in February 2017. Along with a sustained and unfair campaign from the Private Health Insurance industry, it signalled the beginning of negotiations on the future of our industry in Australia.

In November 2016, the Senate referred an inquiry into price regulation associated with the Prostheses List Framework to the Standing Committee on Community Affairs. During the inquiry, MTAA was a strong and effective voice for the industry, providing detailed submissions as well as evidence at the Committee's public hearings. The Association's representation was supported by the submissions and evidence of individual member companies.

A number of MTAA's recommendations and policy positions were adopted or recognised by the Senate Committee in its May 2017 report, and accordingly we welcomed the Committee's recommendations.

The Committee's report noted that medical devices account for only 14 cents in every dollar paid in private health insurance reimbursements and that, while the cost of prostheses is one aspect which influences the costs of private health insurance premiums, increasing community utilisation is a key factor.

Following 5 months of intensive negotiation with Government, on 11 October 2017, MTAA signed a historic Agreement with the Federal Government.

While the Agreement includes further savings to the Prostheses List, it also delivers four years of certainty and stability for the industry and a pathway to broader beneficial reforms. The Agreement also acknowledges the evidence based data put forward by the industry and rejected the misleading claims of \$800 million in savings that were promoted by the Private Health Insurance industry.

This outcome is the result of hard work and advocacy from many at MTAA and from industry. During this financial year, MTAA and members participated in over 100 meetings of various Working Groups, and Committees to develop an evidence based negotiation position and advocacy program. Along with our CEO Ian Burgess, and other members of the MTAA, we increased our advocacy in Canberra with the Minister and key Government and bureaucratic stakeholders.

The four-year Agreement will implement Prostheses List reductions totalling \$303 million per year. These savings are very significant and will undoubtedly result in major impacts on the industry, including job losses, reduced R&D spending, reduced education and training for healthcare professionals and reduced investment in clinical trials.

Key Government commitments in the Agreement

1. No further reductions in Prostheses List benefits during the term of the Agreement unless approved by MTAA.
2. Establishing a \$30 million MedTech and biotech grants program available for small to medium size enterprises (SMEs) and researchers who partner with SMEs for conducting activities that contribute to making patient's lives better through the development of new and innovative technologies.
3. Ensuring patients in the private sector access safe and effective prostheses in a timeframe closer to that of public patients by reducing duplication in assessment between the TGA and the PLAC.
4. Increasing the frequency of listing of the Prostheses

List from two to three times a year. This results in faster access to technologies and ultimately increases the value of private health insurance for patients.

5. Reviewing, through the PLAC, ways of listing non-implantable medical devices to support private health insurance reimbursement for a wider range of clinically effective and cost effective medical devices. This ensures patients in the private sector have access to innovative technologies already available in the public sector and was a key recommendation from MTAA.

The Agreement will provide the industry with much needed stability and allows the industry to do what it does best – assist patients to lead healthier and more productive lives.

Honouring Steadfast Support and Achievement

The MTAA Board firmly believes it is vital for an industry association to have a strong and supportive membership base. We are committed to remaining relevant to all our members. We thank and recognise all our member companies for their contribution to the industry and their support through membership to further the important activities of MTAA.

Each year at the MedTech Industry Awards Dinner, we say a special thank you and recognise those members who have been continuously committed to MTAA for the last 10, 20, 25 and 30 years.

Last year marked 35th years of continuous operations of the Association, and with that we celebrated our founding members who have been with us for all of those 35 years. The following companies reached some big milestones and they were recognised for their support in November when we recognised the following companies for their continuous membership:

For 20 years of continuous membership:

- Boston Scientific

For 30 years of continuous membership:

- Becton Dickinson

For 35 years of continuous membership:

- 3M Healthcare Pty
- Abbott Vascular
- Alcon Laboratories


- Allergan Australia
- Johnson & Johnson Medical
- Smith & Nephew
- Terumo Australia
- W. L. Gore and Associates
- Zimmer Biomet

We also believe it is important to recognise outstanding individuals who have dedicated their careers to the Medical Technology Industry in Australia. We do this by occasionally honouring such people through life membership of the MTAA.

This year we recognised David Ross. During his 15 years with MTAA, David served on several key national committees and provided invaluable advice and support to members on a wide range of issues. Honorary Life Membership of MTAA is awarded to those who have given long and meritorious service to our industry.

In concluding, I would like to say a heartfelt thank you to the MTAA Board and Committee chairs and volunteers for their steadfast support and wise counsel throughout this year. I also recognise the work of our former CEO, Susi Tegen, who stepped down in September 2016 due to ill health. I would like to thank both Allison Fox and Andrea Kunca who jointly managed the Association prior to the appointment of our new CEO, Ian Burgess, in February 2017. Ian has successfully guided the Association through an incredibly challenging period and I am thankful for his support and guidance.

I look forward to the year ahead with renewed optimism given the challenging year the industry has endured. As MTAA members we must continue to highlight the important and life-saving work our industry undertakes in Australia and continue to celebrate our contribution and achievements.



Gavin Fox-Smith
MTAA Chair



Left to Right: Emma Cleary (Device Technologies), Chelsea Cornelius, recipient of the Outstanding Achievement Award 2016 (Analytica) and Gavin Fox-Smith (Johnson & Johnson Medical).



Left to Right: Gavin Fox-Smith and The Hon. Greg Hunt MP.

CEO REPORT

IAN BURGESS



Since commencing as CEO in the second half of 2016-17, MTAA has, by necessity, allocated substantial time and resources to activities related to reform of the Prostheses List and the Agreement with Government.

However, the Association has also maintained broader advocacy and policy development, including regulatory reform; member services such as our professional development program, events and forums; our Women in MedTech initiative; and regular provision of information to members and analysis of healthcare and industry issues.

Regulation Reform

In September 2016, the Government released its Response to the Review of Medicines and Medical Devices Regulation. The reforms will be progressively rolled out by the Therapeutic Goods Administration (TGA) over the next three years.

MTAA is committed to ensuring the benefits of modern, innovative and reliable medical technology are available to patients. As a result, MTAA supported the recommendations of the Review that:

- Improve patient access to innovative medical technologies in a timely manner.
- Remove duplicating regulation that is of no benefit to patient safety but only serves to slow down patient access to medical technology.
- Speed up patient access through the use of international assessments.

MTAA has been an active partner supporting the TGA initiatives to streamline assessment processes whilst ensuring the TGA activities are in line with global best practice. Our position has been to strike a balance between pre-market assessment and post-market monitoring, to avoid delaying patient access to new and improved medical devices that can result in significant benefits to a patient's life, while ensuring devices are safe and effective.

The reforms will provide earlier access to the latest medical devices for patients by:

- Increasing flexibility in the assessment processes (included in the Therapeutic Goods Amendment (2016 Measures No. 1) Bill of June 2017);
- Enabling the establishment of third party conformity assessment bodies in Australia to undertake medical device assessments, which will allow entities other than the TGA to undertake conformity assessments in Australia; and
- Leveraging the use of assessments from comparable overseas regulators to minimise duplicative assessments by the TGA.

MTAA has continued to support the ongoing legislative changes required for the full implementation of the Review of Medicines and Medical Devices Regulation.

Policy and Innovation

During 2016-17, MTAA continued leading the NSW Government's MedTech Knowledge Hub. Following on from the Industry workforce and skills review that was conducted in the previous year, MTAA secured a grant from the NSW Government to engage Deloitte Access Economics to develop a Scoping Paper on the Economic contribution of the medical technology industry. This Scoping Paper will form the basis of a complete economic contribution analysis that is expected to be conducted in 2017-18.

Established to promote clinical trials and research in the medical technology industry, the Clinical Investigations Interest Group (CIIG) comprises ten industry professionals drawn from MTAA members and associate members. The CIIG occupies a unique position within MTAA, facilitating and advocating for clinical research, innovation and science in the Medical Technology Industry.

In May 2016, a successful Clinical Trials Forum was conducted, with a focus on the importance of clinical trials in Australia. In addition, MTAA also became a member of the Research and Development Taskforce which comprises experts in the field and Medicines Australia, and is focusing on activities to promote clinical trials in Australia, including setting up a national body for the coordination of clinical trials and promoting patient participation in clinical trials.

MTAA continues to be active in four national-level clinical registries: the Australian Breast Device Registry (ABDR), Australian Cardiac Outcomes Registry (ACOR), the Bariatric Surgery Registry (BSR) and the National Joint Replacement Registry (NJRR). With the raised importance of data and quality in healthcare, MTAA foresees a rise in registry activity moving forward.

During 2016-17, MTAA collaborated with AusBiotech, BioMelbourne Network, Medicines Australia and Research Australia to highlight to Government the importance of Research & Development (R&D) tax incentives for the MedTech industry. The proposals of the 'Ferris, Finkel, Fraser' Review to limit the R&D Tax Incentive if adopted would have a devastating impact. MTAA proactively engaged with the Government to highlight case studies to show the potential decline in this critical activity by members and the impact to the Australia economy. This advocacy was successful

in delaying implementation of the proposals and will continue in 2017-18, in collaboration with the other key stakeholder organisations.

Similarly, MTAA adopted a successful collaborative advocacy approach with AusBiotech, BioMelbourne Network, Medicines Australia, Research Australia and the Australian Medical Research Institute to achieve restoration of key occupations for the MedTech, research and pharmaceutical sector to the skilled migration visa list. If this had not occurred, the sector would not have been able to access the skills required from overseas following changes by the Government to the 457 Visa requirements. In June 2017, the Federal Government announced that it would reinstate key MedTech occupations on the temporary and permanent skilled visas list, effective from 1 July 2017. It was pleasing that the Government addressed concerns that were widely shared across the industry, health and medical research sectors.

Membership

This year we welcomed nine new voting members and eleven Associate and Affiliate members, taking our membership total to 101. We implemented a new member management system and website to improve the usability of member resources, allowing members to customise the content they receive from MTAA. It allowed us to improve the registration process for training and events and negate the need for using third party systems for the conference. Booking fees and credit card surcharges have been removed.

Financial performance

Sound financial and operational management resulted in a profit of \$106,932 in 2016-17, following losses of \$386,305 in 2015-16 and \$205,711 in 2014-15.



Left to Right: Ian Burgess talks with the Hon. Greg Hunt MP.

Strategic Plan

With an incoming CEO and the 2014-17 Strategic Plan drawing to a close, the MTAA Board commenced a strategic review process in March 2017. A quantitative member survey was conducted in May, with a total of 114 responses being received. Member company CEOs/MDs, authorised representatives, committee members and key member contacts across government affairs, regulatory, reimbursement, compliance and HR/training divisions of member companies were included in the survey.

In addition, qualitative research was conducted as a series of one-on-one in-depth interviews in April and May. This research provided valuable insights from a range of stakeholders, including Government and non-members.

Two facilitated Board workshops were held in March and in June to consider the results of the qualitative and quantitative research and an implementation workshop was conducted with MTAA staff. MTAA's Strategy and Implementation Plan 2017–2020 was subsequently finalised and adopted by the Board in August 2017.

The Strategic Plan has been developed at an important time. Healthcare policy and funding is in flux in Australia and the Medical Technology Industry needs to be represented in policy debates that affect the future. The industry needs to continue to engage with the Government to move forward on a long list of issues, from regulation of combination devices to ongoing reform of the Prostheses List.

MTAA needs to grow, to be increasingly financially strong and to achieve the strategic goals it has set. The plan identifies that the best path to growth is in collaboration with a broad-based alliance that includes researchers, manufacturers, distributors, clinicians, providers, funders and consumers. Collaboration is at the heart of the plan. It widens engagement, expands a base for representation and advocacy, and brings benefits to members.

I look forward to implementing the plan, to engage and re-engage current members, past members and other stakeholders to improve representation and support for relevant projects and advocacy, and to work towards better meeting the needs of MTAA members.

MTAA team

I would like to recognise the extraordinary efforts of the entire MTAA staff during what has been a challenging period. Our dedicated and passionate staff have enabled the Association to “punch above its weight” in terms of the quantity and quality of output from our small team.



Ian Burgess
MTAA Chief Executive Officer



Ian Burgess at the Bennelong Innovation Fair held in March 2017.



BOARD OF DIRECTORS



Maurice Ben-Mayor, President, Stryker South Pacific

B.Sci (UNSW), Executive MBA (AGSM)

Maurice has over 20 years of experience in the Medical Technology industry across senior roles in sales, management, marketing and market access. Maurice has been at Stryker for 14 years and is currently the President of the ANZ Business.

Maurice joined the Board in December 2016 and is a member of the Government Affairs Committee and Chair of the Orthopaedic Special Interest Group.



Paul Braico, Vice President and Managing Director, Boston Scientific

B.Eng (UNSW), MBA (MGSM), GAICD

Paul has 30 years' experience in the medical technology industry, working in diverse organisations including Australian manufacturing, medical equipment, medical distribution, and medical device multinationals. Prior to his current role, Paul has held several senior leadership roles in Australia and Japan.

Paul joined the Board in June 2012 and is a member of the Finance Committee.



Tanja Brycker, General Manager, Teleflex Medical Australia & New Zealand

Post Grad Dip Marketing & Business (UTS), General Management Program (AGSM), GAICD

Tanja has been involved in the Australian Healthcare industry for over 30 years, contributing as a registered nurse, midwife and intensive care nurse specialist for 12 years. For the past 20 years Tanja's involvement in MedTech has evolved through sales, marketing and general management where she spent 16 years building up an Australian owned family business, Mayo Healthcare until it was acquired by Teleflex Medical in 2014.

Tanja joined the Board in August 2016 and is a member of the Women in MedTech and MedTech conference committees.



Emma Cleary, Chief Operating Officer, Device Technologies Australia

B.Bus (Deakin), ICAA, MAICD

Emma has over 25 years' experience within the Medical Device, Managed Services, Professional Accounting and other industries, Emma has held a number of senior management roles both in Australia and internationally. Emma is a Chartered Accountant and joined Device Technologies as CFO in 2005. In addition to her group financial management responsibility, Emma is also responsible for the global operations of Device Technologies. Prior to joining Device Technologies, Emma held leadership positions with Pioneer International, Tenix Group, Ericsson and Bosch across Asia and Australia.

Emma joined the Board in October 2013, was Co-Vice Chair between December 2014 and December 2016 and is Chair of the Finance Committee.



Rebecca Cortiula, MTAA Vice Chair, Managing Director, Terumo Australia

B.Sci (UTS), MBA (AGSM), GAICD

Rebecca has been working within the Australian Healthcare system for more than 20 years. Prior to joining Terumo she worked within the Australian hospital system as a Hospital Scientist in several scientific areas including biochemistry, microbiology, haematology and blood banking. She also worked for the Australian Red Cross Blood Service in the serology laboratories. Rebecca has a broad range of experience including the specialty areas – laboratory science, cardiovascular surgery, interventional radiology and cardiology, transfusion and general hospital medical devices both consumables and capital equipment.

Rebecca joined the Board in November 2015 and was elected Vice-Chair in December 2016. Rebecca is a member of the Women in MedTech committee.



Christopher Cowley, Managing Director, Varian Medical Systems Australasia

MBA (AIB), FAICD, CCEO

Chris was appointed Managing Director of Varian Medical Systems Australasia in 2009, having previously worked for Varian in the Middle East as Service and General Manager. Prior to his employment with Varian he studied, trained and worked as a Biomedical Engineer in the UK. Chris has been in the medical device industry as a customer and vendor for 28 years.

Chris joined the Board in October 2014 and resigned in June 2017. Chris represented the Board on the Code Authority.



Hilary Crilly, Managing Director, Becton Dickinson Australia & New Zealand

MA (OXON), MHPOL (SYD.), CA, MAICD

Hilary has 24 years experience in the pharmaceutical and medical device industries, including 14 years as a corporate office holder, Company Secretary or Director, and is currently Director for BD in Australia and New Zealand. She is a member of the Australian Institute of Company Directors and has 30 years experience as a chartered accountant.

Hilary joined the Board in November 2015 and resigned in November 2016. Hilary was a member of the Finance Committee.



Lyn Davies, Managing Director, Tunstall Australasia

Dip Bus Management, PERSA, AMACS, MAICD

As Managing Director of Tunstall Australasia, Lyn Davies is responsible for the strategic direction, business growth and acquisitions. Lyn has over 20 years' experience in customer service and contact centre environments, and has worked with well-known organisations including Logan City Council, Mater Hospitals, CITEC and the Queensland State Government. Lyn has presented nationally and internationally on assistive technology solutions and holds qualifications in management and IT services. She has previously held the position of Secretary and then Chairperson for the Australian Teleservices Association, and was a double Queensland Finalist in the 2014 Telstra Business Women's Awards.

Lyn joined the Board in December 2013 and is a member of the Women in MedTech Committee and the MedTech Conference Committee.



Steven Flynn, General Manager, Baxter Australia & New Zealand

B.Eng (Mech), Grad Dip Management, MEI (Swinburne)

Steven has responsibility of over 1,100 employees and oversees a significant commercial, manufacturing and compounding pharmacy footprint across Australia and New Zealand. As a current MTAA Board member, Steven has ensured that Baxter is active in advocating directly for MTAA policy platform to deliver benefits to the entire membership. Since 2006, Steven has held senior executive roles in Baxter ANZ and Asia Pacific. Prior to joining Healthcare, Steven worked at TNT and GM Holden Limited.

Steven joined the Board in November 2015 and is a member of the Code Authority and MedTech Conference Committee.



Andrew Fox-Smith, Chief Executive Officer & Director, Global Orthopaedic Technology

B.Bus (CSU), AMP (HARVARD), AICD

Andrew has over 20 years' experience in the Medical Technology Industry and brings broad experience from senior jobs in both multinational companies and Australian small-medium enterprises. Andrew was previously Chairman at Optimized Ortho until its acquisition by Corin and prior to that was Group President International for Stryker where he also sat on the Executive Committee. He joined Global Orthopaedic in July 2014 when he led a management buy-in with other investors.

Andrew joined the Board in April 2017.



Gavin Fox-Smith, MTAA Chair, Managing Director, Johnson & Johnson Medical

B.Sci (USYD), Grad Cert Marketing (Charles Sturt), MBA (Deakin) AFAMI, CPM, GAICD

Gavin has almost three decades experience in the medical technology sector across Australia, New Zealand and the Asia Pacific region. Gavin joined J&J in 1997 as a Regional Business Director and has held diverse leadership roles in sales, marketing and general management across many J&J Medical Devices franchises. Gavin was appointed to his current role of Managing Director Johnson & Johnson Medical Devices ANZ in 2012. Gavin has a strong commitment to the health sector and contribution to the community, with particular interests in Diversity and Inclusion, and was appointed a Male Champion of Change – STEM in 2017.

Gavin joined the Board in April 2012 and was elected Chair in December 2014.



Doug North, Managing Director, Surgical Specialties

BA (EDU)

Doug is the major shareholder and Executive Director of Surgical Specialties. Following Howmedica's integration with Stryker he held the role of General Manager, Stryker NSW. Through 2000 to 2005, Doug established his own business and was the exclusive distributor in NSW/ACT for Smith and Nephew's orthopaedic and endoscopy products. In 2006, Doug established Surgical Specialties, which now employs 90 staff across Australia and New Zealand.

Doug joined the Board in April 2013 and resigned in February 2017.



Mark Taffa, MTAA Vice Chair, Managing Director, Horten Medical

B.Bus (CSU)

Mark is the founder and Managing Director of Horten Medical, a company distributing medical devices, established in 2005. At GE Medical, Mark had product responsibility for all of Asia in digital imaging, based in Singapore and consulting to the Brunei government on e-health. Actively involved in the healthcare industry for over 15 years, Mark has experience in running small scale local manufacturing of complex medical equipment for local and export sales.

Mark joined the Board in December 2013 and was elected Vice-Chair in December 2014. Mark is Chair of the Access Committee.



Andrew Wiltshire, Senior Director, Corporate Affairs, Medtronic Australasia

RN (QLD), BA (Media Studies) (Griffith), MBA (UNE), GAICD

Andrew has over two decades experience in the Australian medical technology and pharmaceutical sectors. As Senior Director, Corporate Affairs, Andrew is actively engaged in efforts to positively promote industry to government, healthcare providers and the community for appropriate access to medical technologies. He oversees Medtronic's government affairs, PR, quality, regulatory and reimbursement initiatives in Australia and New Zealand.

Andrew joined the Board in October 2013 and is Chair of the Government Affairs Committee.

COMMITTEES

Access

The Access Committee is responsible for policy on regulatory and reimbursement issues which impact on market access.

The Access Committee has been heavily involved in contributing to the debate on Prostheses List Reform and the negotiation of the Agreement with Government. Its work has been pivotal in the results achieved by MTAA in 2016-17 for the sector by contributing to the development of the evidence-base which underpins the Agreement, and which will inform its implementation in the next 12 months.

The Committee met seven times to consider issues relating to Prostheses List reform and the Agreement.

As well as approving six internal reports provided by the Working Groups established under the MTAA Prostheses List Reform Strategy, it also contributed to the following MTAA responses:

- The Senate Inquiry into the Prostheses List Framework and various supplementary submissions
- The consultation on the revised terms of reference for the Clinical Advisory Groups and the Health Economics Sub-committee to the PLAC
- The consultation on the targeted review process of Prostheses List benefits
- The consultation on the Melbourne University report to Government on a future PL benefit setting framework
- The consultation on the use of Independent Hospital Pricing Authority (IHPA) data to inform PL reform

Access Committee Members

Mark Taffa, Horten (Chair)
Doug North, Surgical Specialties
George Faithfull, Stryker
Ruth Shennan, Device Technologies
Andrew Wiltshire, Medtronic
Falko Thiele, Biotronik
Fraser Cleave, LifeHealthcare
George Faithfull, Stryker
Iain Hamilton, Johnson & Johnson Medical
Karen Harrison, BBraun
Libby Day, Baxter Healthcare
Michael Simmonds, Boston Scientific
Peggy McBride, St Jude Medical
Peter Yeates, Alcon
Rachael Todd, LivaNova
Robyn Chu, Alcon
Ruth Shennan, Device Technologies
Teresa Farish, Stryker

Code Authority

The Code Authority (CA) Committee role is to ensure effective operation and administration of the Medical Technology Industry Code of Practice (Code).

In 2016-17, the Committee met on 4 occasions to discuss key issues in relation to the intent and interpretation of the Code relating to appropriate locations for third party events, transparent interactions with consumer organisations and branding on small items at third party events. The Committee also dealt with one advertising complaint where it found there had been a moderate breach of the Code and a financial penalty was applied.

Code Authority Committee Members

Nick Shalley, Independent (Chair)
Christopher Cowley*, Board Representative
Dawn de Cruz, Allergan
Henry Ko, Consumer Representative
Hugh Cameron, Becton Dickinson
Jason Neal, W.L Gore
Jessie Yap*, Medtronic
John Quinn, Royal Australasian College of Surgeons
Michelle Wagner, Johnson & Johnson Medical
Steven Flynn, Baxter

**Note: Christopher Cowley resigned on the 5th June 2017*

Steven Flynn was appointed as the Board Representative on Code Authority on the 13th June 2017

Jessie Yap from Medtronic resigned on 13th September 2017

Code Panel

The Code Monitoring Sub-committee's primary objective is to review the dealings between members and Health Care Professionals (HCP's) including, but not limited to company sponsored events, company sponsored third party educational conferences and grants, donations and gifts. In 2016-17, the Sub-committee met 7 times and reviewed a total of 71 reports. No serious breaches of the Code were identified. Some of the key areas of discussion arising from the reporting process related to what is considered to be fair market value for Health Care Professionals acting as consultants, the appropriate expenditure on hospitality and choice of venues for company events.

Code Panel Committee Members

Alan Limbury, Independent (Chair)
Jason Korke, Independent (Chair)
Ken Ramsay, Independent (Chair)
Nick Shalley, Independent (Chair)
Amanda Hickey, Surgical Specialties
Dean Driscoll, Olympus
Gary Burgess, Sirtex
Glen Mason, Johnson & Johnson Medical
Helen Mikolaj, Consumer Representative
Jennifer Mew-Sum, Medtronic
John Stubbs, Consumer Representative
Michael Goldberg, St Jude Medical
Pam Davis, Consumer Representative
Roderick McRae, Australian Medical Association
Sheena Joshi, Atkinson Vinden Lawyers
Susan Dean, Alcon
Trent Enright, Terumo
Wayne Lee, Hospira

**Note: Gary Burgess resigned on the 27th October 2016*

Government Affairs

The Government Affairs Committee is responsible for advocacy and stakeholder engagement on issues that impact on the industry.

In 2016-17, the Government Affairs Committee met 11 times and played a critical role in guiding and participating in stakeholder engagement and advocacy on a range of issues, particularly Prostheses List reform and the Agreement with Government.

It also played a pivotal role in a number of Working Groups established under the MTAA PHI Strategy and oversaw the development of an infographic demonstrating the value of MedTech which has since been used in MTAA's advocacy work. (See page 1)

More broadly, the Government Affairs Committee also provided strategic direction to MTAA on advocacy regarding the following:

- The 457 Visa changes and their impact on the industry through a reduced capacity to bring in workers with the skills required by the sector.
- The changes proposed under the review of the R&D tax incentive commissioned by the Government.
- The changes to the Radiation Oncology Health Program Grants program which saw a reduction in Federal Government funding for radiation oncology service providers.

Government Affairs Committee Members

Andrew Wiltshire, Medtronic (Chair)
Carolyn Cameron, Allergan Australia
David Cain, Johnson & Johnson Medical
George Faithfull, Stryker
Kristine James, LifeHealthcare
Lorna Horsnell, ConMed
Luxin Wang, Alcon

Maurice Ben Mayor, Stryker*
Michael Reynolds, Biotronik
Michael Simmonds, Boston Scientific
Pedro de Paula, Smith & Nephew
Rachael Todd, LivaNova Australia
Richard Dowling, Baxter
Robert Izzard, Smith & Nephew*

** Note: Maurice Ben Mayor resigned on the 9th December 2016
Robert Izzard resigned on the 9th December 2016*

Regulatory Affairs

The Regulatory Affairs Committee is responsible for preparing industry positions and providing detailed feedback requiring hands-on regulatory expertise and experience to MTAA-drafted submissions to TGA consultations and other advocacy efforts. Regulatory Affairs Committee representatives participate actively in the TGA Regulatory and Technical Consultative Forum for medical devices (RegTech) that meets 4 times.

In 2016-17, the Regulatory Affairs Committee met 8 times. Input to RegTech was provided on:

- TGA Business Improvement Program - conformity assessment e-form
- Application audit backlog/status of audit assessments
- Medicines and Medical Devices Regulatory reform
- Updates to TGA guidance documents:
 - Substantial changes (post-market), certificate transfer
 - MDSAP – medical device single audit program
 - Requirements for clinical evidence and clinical experts

Regulatory Affairs Committee Members

Mahesh Datar, Medtronic (Chair)
Ana Cuk*, Becton Dickinson
Andrew Black, Alcon
Brad Sheehan, Five Corners
Cletus Pinto, Hospira
Clive Simon, SPD Company
David Le Cheminant, Life Healthcare
Delwyne Lauten, Abbott Vascular
Fleur Winslade, Terumo
Giselle Rayman, Bard
Juliana William, Baxter
Kevin Samuels, ConMed
Lachlan McKenzie, Stryker
Laleetha Devi, Halyard
Leanne Etherington, Device Technologies
Lopeti Lavulo, Speedx
Lucy Xiao, Boston Scientific
Meryl Musson, Edwards Lifesciences
Michelle Nguyen-Lee, Boston Scientific
Minta Chen, Smith & Nephew
Rachael Bissell, Elekta
Ramon Ippolito, Surgical Specialties
Susanne Winter, Johnson & Johnson Medical
Yih-Fye Freeman, B Braun

**Note: Ana Cuk resigned on the 19th May 2017
Richard Malyn resigned on the 29th June 2017*

Regulatory Sub-committee

This is a sub-committee of the Access Committee and its role is to advise on strategic regulatory matters and to develop industry positions for MTAA.

In 2016-17, the Regulatory Sub-committee met 6 times with additional ad-hoc meetings as needed. In the past financial year, MTAA has made 7 submissions on matters related to the Medicines and Medical Devices Review (MMDR).

Also, MTAA made submissions to Senate Community Affairs Legislative Committee in relation to the Therapeutic Goods Amendment (2016 Measures No. 1) Bill and testified at the inquiry.

MTAA has been the driver in drafting the Vendor Credentialing standard which is now in the public consultation phase. Healthcare facilities rely on meeting accreditation standards as an assurance that patients are safe and that their care is of the highest level. Facilities also wish to ensure that vendors visiting their facility adhere to these standards.

Vendor credentialing is the process of establishing the qualifications of vendors and assessing their background and legitimacy. Healthcare providers may utilise vendor credentialing as a primary criterion to manage the access of vendors to healthcare facilities in general, and/or to certain restricted clinical areas. The goal of creating a national vendor credentialing standard is to minimise the costs to the national healthcare system, simplify the process, avoid unnecessary duplication and protect the privacy rights of individuals. To this end, this Vendor Credentialing Standard was developed by the Standards Australia committee HE-033 Vendor Credentialing for Healthcare Facilities. The Standard makes vendors responsible to ensure and attest that their employees who call on healthcare facilities meet the Standard.

Regulatory Sub-committee Members

George Faithfull, Stryker (Chair)
Christine Cuthbertson, Paragon Therapeutic
Darren Forrest, Medtronic
David le Cheminant, LifeHealthcare
Elizabeth Van Den Akker, Abbott Vascular
Falko Thiele, Biotronik
Gary Burgess*, Sirtex
Hugh Cameron, Becton Dickinson
Jenny Bennell*, St Jude Medical
Mahesh Datar, Medtronic
Mary Kennell, Bard Australia
Rebecca Gaudin, Johnson & Johnson Medical
Renee Hardley, Boston Scientific
Ruth Shennan, Device Technologies
Samantha Tham, Smith & Nephew
Sue Hunter, St Jude Medical

**Note: Jenny Bennell resigned on the 10th May 2017
Gary Burgess resigned on the 26th June 2017*

Reimbursement

The Reimbursement Sub-committee is responsible for providing technical advice on reimbursement matters to the Access Committee.

In 2016-17, the Reimbursement Sub-committee met on 3 occasions. However, the Sub-committee members were heavily involved in a number of Working Groups and therefore the contribution members of this sub-committee have made to the industry has been significant.

Between July and October 2016, more than 40 meetings of the Working Groups were held to deliver the following internal reports:

- The use of international reference pricing to review existing Prostheses List benefits.
- Public/private hospital purchasing arrangements for medical devices and how this influences the pricing of prostheses.
- An industry-agreed benefit setting and review model
- Options to improve the PLAC process.
- Options to allow the Prostheses List to cover medical devices which do not currently meet the criteria under Part A of the Prostheses List.
- A set of agreed principles for the use of clinical registries for reimbursement purposes.
- Specific technologies which are of benefit to patients outside the hospital setting and identification of the barriers.

In addition to the above, the Sub-committee also held a successful meeting with Department of Health Officials in May 2017 allowing identification of opportunities to collaborate to improve existing processes and allow the industry to showcase products. It also provided feedback to the Department which resulted in improvements to the Prostheses List Guidelines and the electronic application management system to facilitate the process for the industry.

Reimbursement Sub-committee Members

Michael Simmonds, Boston Scientific (Chair)
Brett Spence, Prism Surgical
Craig Stamp, Device Technologies
Justin Turpin, Elekta
Karen O'Keeffe, Stryker
Kevin Guinee, Bard
Natalie Lawandi, Medtronic
Michelle Costa, Johnson & Johnson Medical
Michelle Frost, Allergan
Neroli Manning*, Sirtex
Rebecca Schnabel, Allergan Australia
Sarah Griffin, Medtechnique Consulting
Sheryl Dunlop, Zimmer Biomet
Sue John, Open Sesame Consulting
Tara Davis*, Terumo Australia
Tracey Doman, St Jude Medical
Vanessa Xavier, Smith & Nephew

**Note: Neroli Manning resigned in February 2017
Tara Davis was appointed on the 28th March 2017*

SPECIAL INTEREST GROUPS

Clinical Investigations Interest Group

Established to promote clinical trials and research in the medical technology industry, the Clinical Investigations Interest Group (CIIG) is comprised of ten industry professionals drawn from MTAA members and associate members. As part of its efforts to promote clinical trials, the CIIG organised a highly successful Clinical Trials Forum on 11 May 2017 which brought together speakers from the NHMRC, MTPConnect, the NSW Ministry of Health, the University of New South Wales, the University of Sydney, PricewaterhouseCoopers and various MTAA members including Medtronic, Biotronik and Edwards Lifesciences.

The CIIG was also involved in reviewing the Clinical Investigation Research Agreement in conjunction with the NSW Ministry of Health as part of the multi-jurisdictional South-Eastern Border States review process.

Orthopaedic Special Interest Group

A Special Interest Group was established in March 2017 to provide a forum for orthopaedic member companies to engage on issues specific to their sector. This Group met twice in 2017, with a view to identifying areas of mutual interest that would be progressed through 2017-18. This includes the development of a market survey for orthopaedic companies.

Radiation Therapy Special Interest Group

A Special Interest Group was established in December 2016 in response to the Federal Government's announcement which would see significant cuts to the Radiation Therapy Health Program Grant Scheme, impacting on providers of these services and thereby also impacting on the providers of the technology to support these services.


While the group were unable to stop the changes, the need continues to exist for Government to be better informed of the value of Radiation Therapy to both patients and the community. The Group will continue to meet in 2017-18 to advance the advocacy of the value of Radiation Therapy.



Falko Thiele (Biotonik) gives an update on 'How is Australia positioned in the conduct of clinical trials?'



Christy Thiel (Edwards Lifesciences) facilitates the discussion at the MedTech Forum - The Clinical Research Landscape.



MTAA REPRESENTING INDUSTRY

Submissions (July 2016 - June 2017)

- Melbourne University consultation: Options for pricing models and design frameworks for prostheses benefits – December 2016
- Targeted reviews of Prostheses List benefits – December 2016
- The regulatory framework for advertising therapeutic goods – December 2016
- Designation of Australian Conformity Assessment Bodies for Medical Devices – December 2016
- Accelerated assessment of medical devices – Priority Review pathway – December 2016
- Senate Inquiry into the Prostheses List Framework – February 2017
- Revised terms of reference for the Clinical Advisory Groups and the Health Economics Sub-committee to the PLAC – February 2017
- Authorised Prescriber (AP) and Special Access Schemes (SAS) – March 2017
- Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 – March 2017
- Australian regulatory framework for Medical Devices – April 2017
- Options for future regulation of low risk products – May 2017
- Supplementary Submission to the Senate Inquiry into the Prostheses List Framework – May 2017
- Prostheses Costs and benefits paid – June 2017
- Comparable overseas regulators for medical devices – June 2017

External Representation

MTAA with its members, represents industry in a range of different committees, stakeholder forums, conferences and groups. Some of the key representations this year were:

- APACMed Board – Asia Pacific Medical Technology Association
- IHPA – Independent Hospital Pricing Authority (clinical trials framework)
- NHMRC – National Health & Medical Research Council (clinical trials framework)
- NSW Health, Office for Health and Medical Research (clinical trials framework)
- PHMAC – Private Health Ministerial Advisory Committee
- PLAC – Prostheses List Advisory Committee
- RegTech – TGA Regulatory & Technical Consultative Forum (regulations & regulatory framework)
- Standards Australia Council, SA Chairman's Advisory Group (industry sector representation)
- State Health Procurement Departments (procurement issues)
- TGACC – Therapeutic Goods Advertising Code Council (compliance with Advertising Code)
- TICC – TGA Industry Consultative Committee (regulations & regulatory framework)
- TISN HSG – Trusted Information Sharing Network, Health Sector Group (industry sector representation)
- APEC Business Ethics Mentors
- Asia Pacific MedTech Forum
- European MedTech Forum

Representation on Standards Australia standards committees

- HE-003 Medical electrical equipment
- HE-009 Hypodermic equipment – general medical
- HE-012 Surgical implants
- HE-019 Anaesthetic and Breathing Equipment
- HE-030 Biological and clinical evaluation of medical devices
- HE-033 Vendor credentialing
- HE-011 Safe disposal of sharps and clinical wastes

PROFESSIONAL DEVELOPMENT

Professional development training for the medical technology workforce is imperative to keep standards elevated, reduce risk and grow the knowledge base of individuals. The skill and engagement of our workforce is reflected in better medical outcomes for patients, longevity of staff retention and greater stability for our industry.

Every second year the Australian College of Operating Room Nurses (ACORN) Standards are updated and MTAA's face to face and online training programs are updated to reflect the changes. These Standards are important for Medical Company Representatives who are in the Operating Room and provide important support and information on specialised and custom devices.

The Operating Theatre Protocols (OTP) course continues to be the most attended facilitated day training course (Face to Face) by MTAA. This year MTAA facilitated 22 courses and the first course in Perth.

The MTAA Self-Paced Online Code training continued to be a popular course as well as the MTAA facilitated in house training for management and board members.

What our participants are saying about our Operating Theatre Protocols:

"Great presentation style, the connection of theory to real world applications. Presenter was excellent!"

"Presenter was awesome, great time in the operating theatre with the role play."

"I loved the practical component and the catering was fabulous!"

"I particularly liked the fact it was so interactive"

"Presenters made it fun and memorable"

"Well run, on time and real world."

300+

MedTech professional development event attendees

2536

People enrolled Introduction to Code of Practice online training

1450

Participants completed MTAA Operating Theatre Protocols Update 1.6 online training



MEDTECH 2016 ANNUAL CONFERENCE

MedTech2016 took place at the Australian Technology Park Everleigh, Sydney, from 27-28 September and explored themes around developing the blueprint for a stronger Australian MedTech industry. Over 200 industry delegates attended across the two days to hear from key speakers including:

- The Hon. Sussan Ley MP, Minister for Health, Aged Care and Sport
- The Hon. Craig Laundy MP, Assistant Minister for Industry, Innovation and Science
- Bill Ferris AC, Chair of Innovation Australia
- Dr Les Levin, Chief Scientific Officer, EXCITE International (Canada)
- Robert Donnelly, Senior Director, Johnson & Johnson Medical (US)
- Steve Sadler, Chief Technical Officer, Tunstall (UK)
- Andrew Stuart, Deputy Secretary of the Department of Health
- Adjunct Professor John Skerritt, Deputy Secretary of the Department of Health
- Alison Verhoeven, Chief Executive of the Australian Healthcare and Hospitals Association
- Associate Professor David Morgan OAM, Former Chair, Prostheses List Advisory Committee

Gavin Fox-Smith, Chairman of MTAA said:

“Healthcare in Australia is undergoing a fundamental shift in structure and operations.”

“The Medical Technology sector is at the forefront of this change as we continue to collaborate broadly with all stakeholders toward achieving the best health outcomes for all Australians.”

“Our willingness to contribute in a positive way has been acknowledged as constructive, as is demonstrated by the distinguished speakers focusing on policy and innovation.”





MTAA

ANNUAL 2016

CONFERENCE

*The blueprint for a stronger
Australian MedTech industry*

Australian Technology Park, Sydney
27-28 September 2016



MTAA

ANNUAL 2016

CONFERENCE

*The blueprint for a stronger
Australian MedTech industry*

Australian Technology Park, Sydney
27-28 September 2016



Award Dinner Sponsors



Exhibitors & Other Sponsors

- | | |
|--------------------------------|--|
| Healthcare Placement Solutions | The SPD Company |
| Optum | Pharmaceutical & Medical Professionals |
| Illuminate Health Consulting | McCloud Consulting Group |
| PaperScalpelRock | Hogan Lovells |
| Insync Surveys | Critical Scientific Solutions |
| | The University of Sydney, Sydney Medical School |





2016 MEDTECH INDUSTRY AWARDS

The MedTech Industry awards are open to all technology, individuals and companies operating in Australia regardless of membership status. It is a chance for industry to come together and celebrate. A record attendance of 220 people gathered to recognise peers for excellence in Medical Technology and outstanding individual achievement.

Kerrin Rennie Award

The Award is endowed by the Rennie family in memory of Kerrin; a long serving and highly respected member of the Australian medical technology community. Kerrin was a passionate advocate for the contribution of medical technology in extending and improving the quality of life and the Kerrin Rennie Award is a fitting tribute to Kerrin's life of service to this industry.

Entry is open to all medical technology companies based in Australia with a recent product launched in Australia, used in the diagnosis, prevention, treatment or management of disease and disability. The product must demonstrate evidence of:

- innovation
- technical excellence
- significant contribution to improving patient outcomes by improving quality of life.

This is the 10th anniversary of the award and was presented to MediGroup EBI, Stracos 3D Rib Clip as the winner.

Chris Selwa, Managing Director of MediGroup EBI said:

"We're delighted to win the Kerrin Rennie award for the second year running. Winning this prestigious award against stiff competition reflects MediGroup EBI's and the device industry's ongoing commitment to introducing products that significantly improve patient outcomes."

Outstanding Achievement Award

The Outstanding Achievement Award, which was introduced for the first time in 2013. This award is open to individuals who have contributed in a significant and outstanding way to the development of the medical technology industry through improvement to patient outcomes or excellence in leadership and innovation.

Chelsea Cornelius from Analytica was the winner of the Outstanding Achievement Award.

Outstanding Achievement Award 2016: Chelsea Cornelius said:

"I feel very fortunate to be able to make a difference in women's lives through PeriCoach and would like to thank Analytica and Geoff Daly for playing a big part in my journey so far."

"I love what I do and am excited to be part of MedTech in Australia, which is on the crest of something extraordinary. Events like these is what inspire me and make me proud to be part of this industry."

Membership Awards

For continuous support and membership of MTAA, several companies celebrated anniversaries, with our founding members celebrating 35 years.

5 years

- Admedus
- Horten Medical
- Laminar Air Flow
- Tunstall Australasia

10 years

- Hospira
- LifeHealthcare
- Wellspect HealthCare
- Open Sesame Consulting

20 years

- Boston Scientific

30 years

- Becton Dickinson

35 years

- 3M Healthcare
- Abbott Vascular
- Alcon Laboratories
- Allergan Australia
- Johnson & Johnson Medical
- Smith & Nephew
- Terumo Australia
- W. L. Gore and Associates
- Zimmer Biomet

David Ross awarded MTAA Life Membership

David Ross was awarded Honorary Life Membership at the 2016 MedTech Industry Awards Dinner.

For the past 15 years, he has provided invaluable advice and support to members on a wide range of issues. Honorary Life Membership of MTAA is awarded to those who have given long and meritorious service to our industry.



From Left to Right: Chris Selwa (MediGroup EBI) receives the Kerrin Rennie Award 2016 for the 3D Rib clip and Chelsea Cornelius (Analytica) receives the Outstanding Achievement Award 2016.



Left to Right: David Ross and Gavin Fox-Smith.

EVENTS

MTAA meeting with students at Australia Catholic University


CEO Ian Burgess spoke to Biomedical Science students at the Australian Catholic University (ACU), North Sydney Campus in May 2017. This initiative is intended to broaden students' understanding of the MedTech industry, its contribution, the key skills, career pathways and professional development opportunities in the sector.



MTAA CEO Ian Burgess visits Biomedical Science students at ACU.

Bennelong Innovation Fair

MTAA along with a number of members attended the Bennelong Innovation Fair in March 2017. The event held in the Great Hall in Parliament House was well attended by Government, with the Prime Minister Malcolm Turnbull, Minister for Health Greg Hunt, Minister for Industry, Innovation and Science Arthur Sinodinos, Minister for Trade Steven Ciobo, Minister for Foreign Affairs Julie Bishop and other Government Ministers and parliamentarians present.



The Hon. Greg Hunt MP observes a demonstration of MedTech at the Bennelong Innovation Fair 2017.

MTPConnect Roundtable

In December members attended a roundtable discussion on the MTPConnect Sector Competitiveness Plan. MTAA hosted two events in both Sydney and Melbourne to help drive this Plan.

Standards Australia Forum

In December Standards Australia, in conjunction with MTAA, invited stakeholders to participate in a half-day forum to explore international standardisation and alignment within the area of medical devices.



From Left to Right: MTPConnect CEO Sue MacLeman with MTAA CEO Ian Burgess.



IVD Regulatory Update Forum

In November we held a forum facilitated by Dr Wendy-Jane Morrow, (CEO IVD Australia) and presentations by Euan Miller (TGA), Alan Edgecomb & Lopeti Lavulo (Speedx). Topics included the regulatory framework (in Australia & abroad), IVD industry update, challenges for sponsors & local manufacturers experience. The presentations produced considerable insight and raised several questions from the audience.



From Left to Right: Dr Wendy-Jane Morrow (IVD Australia) and Alan Edgecomb were both speakers at the IVD Regulatory Update Forum.

HR/Training Roundtable

In response to the release of the Workforce Skills report produced by Deloitte and commissioned by MTAA on behalf of the NSW Medtech Knowledge hub, MTAA together with the Australia Catholic University hosted a HR Roundtable in March 2017 with over 30 HR industry leaders. They were asked to consider: *“How do we educate our people to better face disruption and challenge?”* and explore ways to build relationships with universities and develop industry specific learning and development opportunities.



Members discuss “disruption” at the HR Roundtable at ACU.

Australian MedTech Innovation - The Clinical Research Landscape

This full day MedTech forum in May 2017 provided an update of ongoing reforms in Clinical research, implementation progress, roadblocks and success seen thus far to inform whether the long-term goal of leading the world in clinical trial research is attainable. In addition, sponsors, start-ups and researchers discussed and shared their invaluable experience from years of conducting medical device clinical trials in Australia.



The MedTech forum allows Members to engage with clinical researchers to discuss collaboration pathways in medical technology.



OUR MEMBERS

Members

3M Healthcare
Abbott (Vascular) Australasia
Abbott Vision
Admedus Australia
Alcon Laboratories Australia
Allergan Australia
Analytica
Australasian Medical & Scientific
Australian Dermatology Equipment
B Braun Australia
Bard Australia
Baxter Healthcare
Becton Dickinson
Biotronik Australia
Boston Scientific
Brainlab Australia
ConMed Australia
Cook Australia
Corin Australia
Critical Scientific Solutions
Culpan Medical Australia
Deutsch Medical
Device Technologies Australia
Edwards Lifesciences
Elanra Medical
Elekta
Fresenius Kabi Australia
Gel Works
GLIA Diagnostics
Global Orthopaedic Technology
Grey Innovation
Halyard Australia
Hologic Australia
Horten Medical
Hospira
iNova Pharmaceuticals Australia
Johnson & Johnson Medical
KLS Martin Australia

Laminar Air Flow
LifeHealthcare
LivaNova Australia
Lumen Health
Materialise Australia
Matrix Surgical
Medical Specialties Australia
Medigroup Australia
Medtronic Australasia
Metacure Australia
Molnlycke Healthcare
Nevro Medical
Olympus Australia
Paragon Therapeutic Technologies
Powervision Inc
Prism Surgical Designs
REM Systems
Reveale Surgical
Simavita
Sirtex Medical Limited
Smith & Nephew
Smiths Medical Australasia
Spectrum Surgical
Speedx
St. Jude Medical Australia
Stryker Australia
Surgical Specialties
Teleflex Medical Australia
Terumo Australia
Tunstall Australasia
Varian Medical Systems Australasia
W. L. Gore and Associates Australia
Wellspect HealthCare Australia
Wright Medical Australia
Zimmer Biomet

Note: Members listed as of 30th June 2017.



Associate Members

Atkinson Vinden Lawyers
Australian Medtech Services
Bizcaps Software
Brandwood Biomedical
Certification Body Australia
Covance
Cutlass Pharmed Regulatory Services
DHL Supply Chain Australia
Elementum Advisory
Five Corners
Gadens
Healthcare Placement Solutions
hTrak
IDE Group
Illuminate Health Consulting
Insight Strategy
Medtechnique
NetDimensions Australia
Open Sesame Consulting
PaperScalpelRock
Regulatory Concepts
SJ Alder
Slate Hill Consulting
Smartways Logistics
Sue Akeroyd & Associates
The SPD Company

Honorary Members

Ms Pam Davis
Mr Stephen Fogarty
Mr Barry Jones
Mr Graham Murphy
Mr Bernard O'Connor
Mr Brian Vale
Mr John Whiteford
Mr Peter Ord
Mr David Ross



Medical Technology
ASSOCIATION OF AUSTRALIA

Level 12, 54 Miller Street
North Sydney, NSW 2060
Phone: 02 9900 0600

Email: mtaa@mtaa.org.au
Web: www.mtaa.org.au
ABN: 61 129 334 354